Evidence map›Paper›PMID 30200994›Full record

ArticleBMC medical genomics2018

TAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data.

Readman Chiu, Ka Ming Nip, Justin Chu, Inanc Birol

Abstract read
In one paragraph

Article in BMC medical genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Mismatch-tolerant, alignment-free sequence classification using multiple spaced seeds and multiindex Bloom filters.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  7. Fusion-Bloom: fusion detection in assembled transcriptomes.Bioinformatics (Oxford, England) · 2020
    Article
  8. Base excision repair deficiency signatures implicate germline and somaticCold Spring Harbor molecular case studies · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Readman ChiuCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 100-570 West 7th Ave, Vancouver, BC, V5Z 4S6, Canada.ORCID 0000-0002-2215-5535
Ka Ming NipCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 100-570 West 7th Ave, Vancouver, BC, V5Z 4S6, Canada.
Justin ChuCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 100-570 West 7th Ave, Vancouver, BC, V5Z 4S6, Canada.
Inanc BirolCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 100-570 West 7th Ave, Vancouver, BC, V5Z 4S6, Canada. ibirol@bcgsc.ca.

Funding

De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER)R01HG007182 · NHGRI · PROVINCIAL HEALTH SERVICES AUTHORITY · PI BIROL, INANC · 2014 to 2022
$1.9M
CIHRNHGRI NIH HHS R01 HG007182
6 · The paper itself

Abstract

backgroundRNA-seq is a powerful and cost-effective technology for molecular diagnostics of cancer and other diseases, and it can reach its full potential when coupled with validated clinical-grade informatics tools. Despite recent advances in long-read sequencing, transcriptome assembly of short reads remains a useful and cost-effective methodology for unveiling transcript-level rearrangements and novel isoforms. One of the major concerns for adopting the proven de novo assembly approach for RNA-seq data in clinical settings has been the analysis turnaround time. To address this concern, we have developed a targeted approach to expedite assembly and analysis of RNA-seq data.

resultsHere we present our Targeted Assembly Pipeline (TAP), which consists of four stages: 1) alignment-free gene-level classification of RNA-seq reads using BioBloomTools, 2) de novo assembly of individual targets using Trans-ABySS, 3) alignment of assembled contigs to the reference genome and transcriptome with GMAP and BWA and 4) structural and splicing variant detection using PAVFinder. We show that PAVFinder is a robust gene fusion detection tool when compared to established methods such as Tophat-Fusion and deFuse on simulated data of 448 events. Using the Leucegene acute myeloid leukemia (AML) RNA-seq data and a set of 580 COSMIC target genes, TAP identified a wide range of hallmark molecular anomalies including gene fusions, tandem duplications, insertions and deletions in agreement with published literature results. Moreover, also in this dataset, TAP captured AML-specific splicing variants such as skipped exons and novel splice sites reported in studies elsewhere. Running time of TAP on 100-150 million read pairs and a 580-gene set is one to 2 hours on a 48-core machine.

conclusionsWe demonstrated that TAP is a fast and robust RNA-seq variant detection pipeline that is potentially amenable to clinical applications. TAP is available at http://www.bcgsc.ca/platform/bioinfo/software/pavfinder.

Indexed as

Genetic VariationUser-Computer InterfaceGenomicsHumansINDEL MutationLeukemia, Myeloid, AcuteRNARNA SplicingSequence Analysis, RNARNAAcute myeloid leukemiaAlternative splicingClinical genomicsGene fusionInternal tandem duplicationPartial tandem duplicationRNA-seqTranscriptome assembly

Identifiers

PMID30200994
PMCPMC6131862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.